Publications by authors named "David R Rutledge"

Claim this Profile
S
Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions).
David E Kandzari, Annapoorna S Kini, Dimitri Karmpaliotis, Jeffrey W Moses, Pradyumna E Tummala, David R Rutledge

JACC Cardiovasc Interv· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Philippe Généreux, David R Rutledge, Tullio Palmerini, Adriano Caixeta, Elvin Kedhi

Circ Cardiovasc Interv· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study.
James B Hermiller, David R Rutledge, Vivian W Mao, Weiying Zhao, Jin Wang

Catheter Cardiovasc Interv· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study.
Krishnankutty Sudhir, James B Hermiller, Srihari S Naidu, Timothy D Henry, Vivian W Mao, David R Rutledge

Catheter Cardiovasc Interv· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.
Connie N Hess, Sunil V Rao, David F Kong, Julie M Miller, Kevin J Anstrom, David R Rutledge

Am Heart J· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.
James B Hermiller, David R Rutledge, Luis Gruberg, John N Katopodis, William Lombardi

J Interv Cardiol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
Srihari S Naidu, Mitchell W Krucoff, David R Rutledge, Vivian W Mao, Weiying Zhao

JACC Cardiovasc Interv· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).
Mitchell W Krucoff, David R Rutledge, Luis Gruberg, Lalitha Jonnavithula, John N Katopodis

JACC Cardiovasc Interv· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis